OncoSec Medical Inc (ONCSQ)

[Waitforit53]

"We believe we can unlock the larger checkpoint market across multiple cancer types by turning 'cold tumors' to 'hot tumors' with our intratumoral IL-12 immunotherapy or 'TAVO.' Our data have demonstrated TAVO's ability to do so by recruiting more tumor infiltrating lymphocytes (TILs) into the tumors. In doing so, TAVO can pave the way for checkpoints to be effective in the largest, but still unresponsive, segment of the checkpoint market," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec.

From June 28, PR.

It has always been a challenge in determining a market value for ONCS over the years and I have always longed for a buyout--until now. I only thought of Keytruda as the only future PD-1, BUT PD-1('s) is now the opportunity across MULTIPLE indications. This potential also creates greater leverage for ONCS in the "takeover" market.